Anti-gallbladder cancer activities and toxicity studies of glycyrrhetinic acid derivative as a novel PPARγ agonist
Our findings suggest that PG-4c holds strong potential as an effective chemotherapeutic candidate for gallbladder cancer. Given that PPARγ agonists are clinically approved drugs for dyslipidemia and diabetes, this class of agents may represent a promising new therapeutic approach for gallbladder cancer management.
Authors
- Yunxue Zhao (ORCID: https://orcid.org/0000-0003-3670-9436)
- Haizhang Ma
- Juan Sun (ORCID: https://orcid.org/0000-0001-6099-2193)
- Yuan Xia (ORCID: https://orcid.org/0000-0002-7292-8903)
- Tao Sun (ORCID: https://orcid.org/0000-0002-7575-3483)
- Chunyan Ji (ORCID: https://orcid.org/0000-0003-4438-1768)
- Gaozhong Xiong
- Qi Mei (ORCID: https://orcid.org/0000-0002-9826-5044)
- Min Liu (ORCID: https://orcid.org/0000-0003-3965-846X)
Institutions
- Shandong University (CN)
- Zhejiang University of Science and Technology (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1704994
- Primary Topic
- Pharmacological Effects of Natural Compounds
- Type
- article
- Field-Weighted Citation Impact
- 0.00